pariglasgene brecaparvovec-opnr
| Brand name | GENGLYCOS |
|---|---|
| Active ingredient | pariglasgene brecaparvovec-opnr |
| Strength | 3x10^13VG/ML |
| Dosage form | Suspension |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | August 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.